
Alcobra axes ADHD drug after Phase 3 failure
pharmafile | January 18, 2017 | News story | Research and Development | ADHD, Alcobra, metadoxine
Israeli-based firm Alcobra is to pull the plug on its experimental attention deficit hyperactivity disorder (ADHD) drug metadoxine after it failed to show any efficacy over placebo in a Phase 3 trial, wiping 50% from the company’s value.
Using the Conners’ Adult ADHD Rating Scales (CAARS) as a reference point, top-line results from the trial indicated that the drug was no better than placebo at managing symptoms of the illness, with Alcobra announcing that it has no plans to continue its development. President and chief executive Dr Yaron Daniely stated: “We consider the negative findings of the study to be conclusive…We are exceedingly disappointed with these top-line results.”
Daniely stated in a conference call that the company now plans to conduct a full data review in order to provide direction to investors in the coming weeks with a new strategic plan.
The same trial was also interrupted by the FDA in September 2016 after it was reported that metadoxine potentially caused damage to peripheral nerve function in animal studies. The FDA later lifted its hold on the trial in December.
Matt Fellows
Related Content

Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

ADHD coach and breathwork experts to run workshop for ADHD management
ADHD coach John Harrington and breathwork facilitator Martin O’Toole will collaborate on ‘Breathwork for ADHD …

NICE recommends digital tech for ADHD diagnosis in children and young people
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory …






